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(4)	 𝑃𝑟𝑜𝑡𝑒𝑖𝑛 = 	 45FGH×IJ
KLMNOPMNQO	PQKRRNRNKOM	(TU)












WT	OXA-48		 28.147	 63940	 8.1	
OXA-48	S118G	 28.117	 63940	 8.1	
OXA-48	R206A	 28.062	 63940	 7.2	




















































































































Penicillin	 Ampicillin	 -820	 0.000716	 235	
Cephalosporin	 Cefepime			 -10000	 0.003200	 260	
Carbapenem	 Imipenem	 -9000	 0.004027	 300	
Cephalosporin/	
reporter	substrate	
















(5)		 𝑆𝑢𝑏𝑠𝑡𝑟𝑎𝑡𝑒 = 	 KO[	45\NONMN]^	45 ×[N^_MNQO	R]PMQ`
∆U
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1=N23A 2=H23A 3=H23R 4=H23B 5=PKpDEST17
Amplicon results from 13.10.2015 - Transformation of OXA-23 to Arctic express, Rosetta and BL21
M 1 2 3 4 5a)
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His-tagged OXA-23 in
Arctic Express cells
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OXA-48 S118G OXA-48 R206A OXA-48 R250A
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Parameter	 S118G	 R206A	 R250A	
X-ray	source		 ID23-2	 14.1	 14.1	
Data	collection	statistics	
Space	group		 C	2	2	21	 P	65	2	2		 P	65	2	2	








			α,	β,	λ	(°)	 90,	90,	90	 90,	90,	120	 90,	90,	120	
Resolution	range	(Å)		 48.95-1.58	(1.64-1.58)	 47.49-2.61	(2.7-2.61)	 47.87-2.35	(2.43-2.35)	
Total	reflections		 1359139	(126159)	 295216	(27309)	 414326	(38262)	
Unique	reflections		 287177	(28517)	 21396	(2038)		 30205	(2885)		
Multiplicity	 4.7	(4.4)	 13.8	(13.4)	 13.7	(13.3)		
Completeness	 1.0	(1.0)		 0.99	(0.98)	 1.0	(0.98)	
Mean	( 𝐼 / 𝜎𝐼 )	 9.96	(1.20)		 10.52	(1.53)		 11.07	(1.70)		
Wilson	B	factor	(Å2)	 17.96	 43.95	 32.12	





Reflections	used	for	Rfree		 14516	(1387)	 1069	(101)		 1510	(145)		
R-factora		 0.164	(0.294)	 0.194	(0.293)		 0.184	(0.243)		




			Macromolecules		 11825	 4015	 4048	
			Ligandsb	 3	 None	 9	
			Protein	residues		 1447	 482	 486	
RMSD	bond	lengths	(Å)	 0.008	 0.018	 0.016	
RMSD	bond	angles	(°)	 0.89	 1.13	 1.06	
Ramachandran	favored	(%)	 98	 95	 98	
Ramachandran	allowed	(%)	 2.2	 4.3	 2	
Ramachandran	outliers	(%)		 0	 0.61	 0	
Rotamer	outliers	(%)	 0	 1.4	 0.47	
Clashscore		 4.97	 5.15	 3.54	
Avarage	B-factor	(Å2)	 24.19	 47.66	 27.48	
			Macromolecules		 22.23	 47.74	 27.46	
			Ligands		 19.17	 None	 33.92	
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Ampicillin	 41.2	 28.5	 691	x	103	 0.4	
Nitrocefin	 251.5	 493	 1960	x	103	 0.2	




Ampicillin	 281.4	 586.4	 2083	x	103	 1.2	
Nitrocefin	 154.5	 1523	 9857	x	103	 0.95	




Ampicillin	 47.1	 21.8	 462	x	103	 0.3	
Nitrocefin	 471.9	 743.9	 1576	x	103	 0.15	




Ampicillin	 405.3	 691.9	 1707	x	103	 1	
Nitrocefin	 95.2	 987.6	 10373	x	103	 1	
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4. Discussion		
	
4.1 	The	β-lactamase	enzymes	OXA-23	and	OXA-24	
	
4.1.1 Restriction-free	cloning	of	His-tagged	and	native	blaOXA-23	and	blaOXA-24	
	
Amplification	of	blaOXA-23	and	blaOXA-24	MPs	
According	to	the	gel	electrophoresis	results	(figure	3.1)	and	the	DNA	concentration	
measurements,	the	amplification	of	the	His-tagged	and	native	blaOXA	MPs	seemed	to	have	
been	successful.	The	double	binding	of	the	R1	primers	for	the	native	and	His-tagged	blaOXA-24	
constructs	was	negated	by	separating	the	two	gene	products	on	a	gel,	and	cutting	out	the	
correct	one.		
	
Challenges	with	cloning	of	the	His-tagged	blaOXA	constructs	
Both	the	His-tagged	blaOXA	constructs	proved	challenging	to	clone	successfully.	In	the	gel	
results	after	the	EMP	reaction,	both	the	His-tagged	constructs	showed	on	the	gel,	but	the	
bands	were	very	weak	compared	to	the	bands	for	the	native	blaOXA	constructs.	The	gel	
results	from	the	amplicon	screening	after	transformation	to	E.	coli	XL1-blue	cells	did	not	
show	bands	for	either	of	the	His-tagged	blaOXA	constructs,	and	only	the	His-tagged	blaOXA-23	
construct	was	purified	and	sequenced.		
	
The	PCR	reaction	with	the	TEV-site	MP,	where	the	His-tagged	MPs	are	elongated	by	21	bps,	
was	not	analyzed	by	gel	electrophoresis,	as	bands	with	a	size-difference	of	only	21	bps	
would	not	have	been	separated	on	the	gel.	So	the	result	of	the	reaction	was	not	verified	
immediately.	However,	the	TEV-site	MP	used	in	this	reaction	can	possibly	account	for	the	
error	later	observed	in	the	sequencing	of	the	His-tagged	blaOXA-23	construct;	the	duplicated	
region	in	the	sequenced	gene	(figure	3.4)	matches	exactly	with	the	21	bp	long	region	of	the	
TEV-site	MP	that	is	constructed	to	elongate	the	His-tagged	blaOXA-23	MP	at	the	5’-end.	How	
this	has	happened	is	however	unclear,	and	the	same	sequence	TEV-site	MP	have	been	
successfully	used	by	Ph.D.	student	Bjarte	A.	Lund	in	previous	cloning	protocols.		
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The	same	duplication	can	have	occurred	in	the	His-tagged	blaOXA-24	construct	as	well,	but	the	
gene	was	not	sequenced,	so	this	cannot	be	confirmed.	The	duplicated	sequence	was	located	
in	the	region	of	the	MP	that	overlapped	with	the	pDEST17	vector,	so	if	the	error	did	occur	
during	the	insertion	of	TEV-site	PCR,	this	would	explain	the	weak	bands	in	the	gel	results	
after	the	EMP	reaction,	where	the	MPs	were	to	be	inserted	into	the	pDEST17	vector.		
	
Cloning	of	the	native	blaOXA	constructs		
The	gel	results	after	the	EMP	reaction	of	the	native	blaOXA	constructs	yielded	strong	bands,	
as	did	the	gel	results	from	the	amplicon	screening	after	transformation	to	E.	coli	XL1-blue	
cells,	indicating	a	successful	cloning	process.	The	sequencing	of	the	native	blaOXA-24	construct	
confirmed	the	correct	gene	sequence.	The	sequencing	of	the	native	blaOXA-23	construct	was	
only	done	with	the	rev.	T7	primer,	meaning	that	it	was	only	sequenced	from	the	T7	
terminator	and	backwards.	Generally,	the	read-length	is	700-800	bases	when	using	a	50	cm	
capillary	running	on	an	ABI	3130x	Genetic	Analyzer,	but	this	depends	on	DNA	concentration,	
purity	and	base	composition	[62].	In	this	case,	the	native	blaOXA-23	gene	was	only	confirmed	
from	base	139	to	the	end	of	the	gene,	because	of	a	too	short	read-length.	If	the	fwd.	T7	
primer	had	been	used	as	well,	the	gene	would	have	been	read	both	ways,	and	in	that	way	all	
bases	had	been	covered	even	with	a	short	read-length.		
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4.1.2 Protein	expression	of	native	and	His-tagged	OXA-23	and	native	OXA-24		
	
Protein	expression	attempts	of	native	and	His-tagged	OXA-23	
Expression	screening	of	native	and	His-tagged	OXA-23	was	done	in	four	different	E.	coli	cell	
lines:	Arctic	Express,	Rosetta2(DE3)plysS,	BL21(DE3)plysS	and	BL21(DE3)pRare,	but	with	
negative	results	with	respect	to	large-scale	protein	expression.	Using	the	Rare	Codon	
Calculator	(RaCC)	server	at	NIH	MBI	[64],	several	rare	codons	for	the	OXA-23	gene	was	
reported	when	expressed	in	E.	coli.	Rare	codons	are	defined	as	codons	used	by	E.	coli	at	a	
frequency	of	less	than	1%	[65];	during	protein	synthesis	this	may	lead	to	depletion	of	the	
low-abundance	tRNAs	in	the	E.	coli	expression	host,	which	again	leads	to	poor	expression	of	
the	target	protein	[66].	A	potential	solution	to	this	codon	bias	is	to	optimize	the	codons	in	
the	blaOXA-23	gene	for	expression	in	E.	coli,	through	the	use	of	a	synthetic	gene	where	the	
problematic	codons	are	replaced	with	codons	commonly	used	in	E.	coli.	Previous	studies	
have	reported	using	a	custom	synthesized	blaOXA-23	gene,	optimized	for	E.	coli	expression,	
resulting	in	a	successful	protein	expression	[27].		
	
Protein	expression	attempts	of	native	and	His-tagged	OXA-24	
Protein	expression	of	OXA-24	was	attempted	in	several	different	volumes	of	both	LB	and	TB	
using	E.	coli	cell	line	BL21(DE3)pLysS	as	expression	host,	but	a	large	scale	expression	of	the	
protein	was	not	successful.	It	remains	unclear	as	to	why	the	induction	of	the	OXA-24	protein	
was	so	inconsistent.	Induction	was	observed	several	times	in	5	mL	LB,	but	this	volume	is	
impractical	for	large-scale	expression.	In	100	mL	LB,	strong	induction	was	observed	once	
during	the	induction	volume	screening,	but	not	in	any	of	the	ten	samples	of	100	mL	LB	
during	the	large-scale	induction	attempt.	Other	studies	have	reported	successful	expression	
of	an	OXA-24	gene	from	an	A.	baumannii	clinical	isolate,	using	E.	coli	BL21	as	host	[35,	67].		
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4.2 	OXA-48	mutations	S118G,	R206A	and	R250A		
	
4.2.1 Site	directed	mutagenesis,	protein	expression	and	purification	of	OXA-48	mutants	
S118G,	R206A	and	R250A		
	
Site	directed	mutagenesis,	transformation	and	sequencing	of	OXA-48	mutants	S118G,	R206A	
and	R150A	
The	Phusion	mutagenesis	reaction,	where	the	three	mutations	S118G,	R206A	and	R250A	
were	introduced	in	the	blaOXA-48	genes,	were	successful	for	all	mutations.	The	sequencing	
confirmed	the	correct	blaOXA-48	sequence,	with	the	three	mutations	in	place.		
	
Protein	expression	of	OXA-48	mutants	S118G,	R206A	and	R250A	
Both	the	small	and	large-scale	protein	expression	of	the	OXA-48	mutants	in	E.	coli	cell	line	
BL21Star(DE3)pRare	resulted	in	induction.	The	SDS-PAGE	analysis	from	the	large-scale	
induction	did	not	show	very	strong	bands,	but	this	may	have	been	due	to	overloading	of	
sample	on	the	gel;	as	seen	in	the	AFI	bands	in	figure	3.12,	the	lanes	look	smeared	and	the	
bands	are	not	very	clear.	Expression	host	screening	was	not	performed,	as	the	
BL21Star(DE3)pRare	cell	line	had	previously	proven	effective	for	WT	OXA-48	in	experiments	
done	by	Ph.D.	student	Bjarte	A.	Lund	[39].		
	
Purification	of	OXA-48	mutants	S118G,	R206A	and	R250A	
The	SDS-PAGE	analysis	after	purification	of	the	three	OXA-48	mutants	indicated	a	purity	of	
over	95%	for	all	three	mutants,	which	is	pure	enough	to	use	in	crystallization	screens	and	
enzyme	kinetics	studies	[68].	For	the	S118G	mutant,	the	purification	yielded	a	very	high	
amount	of	protein,	with	an	end	result	of	173	mg.	The	purification	of	the	R206A	and	R250A	
yielded	50	mg	and	12	mg	protein,	respectively,	which	is	enough	to	set	up	crystallization	
screens	and	do	enzyme	kinetics	studies.		
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4.2.2 Protein	crystallization,	X-ray	data	collection	and	modelling	of	the	three	OXA-48	
mutants	S118G,	R206A	and	R250A	
	
Crystallization	and	crystal	quality		
The	three	mutant	crystals	were	grown	using	the	same	conditions,	and	for	all	three	mutants	
the	conditions	in	row	C	and	D	(table	2.9)	seemed	to	yield	better	quality	crystals	then	row	A	
and	B	conditions.	This	observation	was	based	on	the	crystals	size	and	shape;	the	crystals	in	
row	A	and	B	were	generally	smaller	and	had	a	prominent	needle	shape,	while	the	crystals	in	
row	C	and	D	were	larger	and	had	a	more	three-dimensional	structure.	When	stored	in	room	
temperature,	relatively	large	crystals	were	obtained	after	only	one	night	for	all	mutant	
screens;	if	the	growth	rate	is	too	high,	it	might	lead	to	poor	crystal	quality,	as	new	protein	
molecules	binds	in	a	non-optimal	orientation	to	the	crystal	surface	[69].	The	R250A	mutant	
crystals	were	therefore	grown	on	4°C	to	slow	the	crystal	growth.				
	
Structures	of	OXA-48	mutants	S118G,	R206A	and	R250A	
All	the	structure	maps	showed	that	the	mutations	were	there.	In	both	the	S118G	and	R250A	
mutants,	two	new	water	molecules	had	replaced	the	serine	and	arginine	residues.	The	
S118G	structure	did	not	show	bound	avibactam,	although	the	crystal	had	been	soaked	in	the	
inhibitor.	If	this	was	a	result	of	the	mutation,	it	would	show	the	importance	of	the	S118G	
residue	in	the	binding	of	avibactam.	But,	there	have	been	some	uncertainties	with	respect	to	
the	validity	of	the	avibactam	sample	used	in	this	experiment,	as	it	has	a	different	color	than	
previously	used	avibactam	samples.	
	
The	R206A	structure	was	refined	to	the	poorest	resolution	of	the	three	mutants	(2.61	Å),	
and	the	Rfree	value	(0.28)	was	significantly	higher	than	the	R-factor	(0.19).	This	can	be	
evidence	of	an	artificially	low	R-factor,	and	it	could	have	been	beneficial	to	have	refined	the	
structure	to	a	lower	resolution.	But	the	validity	of	the	R206A	structure	is	supported	by	the	
S118G	and	R250A	structures,	which	were	both	refined	to	fairly	high	resolutions	with	good	R-
factor	and	Rfree	values.			
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Enzyme	kinetics	studies	on	the	three	OXA-48	mutants	S118G,	R206A	and	R250A	in	comparison	
with	the	OXA-48	WT	
The	kinetics	results	for	the	WT	OXA-48	are	consistent	with	the	expected	substrate	profile	of	
the	OXA-48	enzyme,	and	correlates	well	with	previous	enzyme	kinetics	studies	done	on	OXA-
48	[24]:	the	enzyme	is	reported	to	hydrolyze	penicillins	at	a	high	level,	carbapenems	at	a	low	
level,	and	cephalosporins	at	very	low	levels	that	borders	to	no	activity	[20].	The	WT	OXA-48	
in	this	experiment	showed	highest	activity	towards	ampicillin	(penicillin)	followed	by	
imipenem	(carbapenem),	but	did	not	hydrolyze	cefepime	(cephalosporin).		
	
The	OXA-48	mutant	R206A	showed	very	similar	activity	levels	as	the	WT	OXA-48.	The	
mutation	is	on	the	surface	of	the	protein	where	two	OXA-48	enzymes	interact	to	form	a	
dimer.	Both	the	model	structure	and	the	size-exclusion	chromatography	results	suggested	
that	the	mutation	did	not	have	an	effect	on	the	dimerization	of	the	protein,	so	the	mutant’s	
similar	activity	profile	as	the	WT	is	not	surprising.	If	the	mutation	has	been	strong	enough	to	
break	up	the	dimer	interaction,	it	would	have	been	interesting	to	see	the	effect	on	the	
enzyme	activity.		
	
The	S118	residue	is	located	in	the	active	site	of	the	enzyme,	and	interacts	with	the	β-
lactamase	inhibitor	avibactam	through	a	hydrogen	bond	[35].	Previous	studies	on	the	class	A	
β-lactamase	enzymes	KPC-2	and	SHV-1	have	illustrated	the	importance	of	the	S118	
equivalent	residue	S130	with	respect	to	avibactam-inhibition;	S130G	mutations	in	the	
enzymes	caused	significant	resistance	to	inhibition	by	avibactam,	and	the	kcat/Km	values	
against	relevant	carbapenems	was	greatly	lowered	when	compared	to	the	wild	type	
enzymes	[70,	71].	The	activity	of	the	S118G	mutant	was	lowered	by	60%	for	ampicillin	and	
98%	for	imipenem	when	comparing	the	kcat/Km	values	to	the	kcat/Km	values	of	the	WT	OXA-
48.	This	shows	that	the	S118	residue	have	an	important	impact	the	OXA-48	enzyme’s	ability	
to	hydrolyze	β-lactams.	Unfortunately,	no	studies	were	performed	on	the	mutation’s	effect	
on	avibactam-inhibition.	
	
The	R250	residue	is	also	located	in	the	active	site	of	the	enzyme	and	interacts	with	
avibactam	through	a	hydrogen	bond.	The	activity	of	the	R250A	mutant	was	significantly	
lowered	when	compared	to	the	WT	OXA-48,	with	kcat/Km	values	for	ampicillin	lowered	by	
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70%	and	kcat/Km	values	for	imipenem	lowered	by	98%.	This	suggests	that	the	R250	residue	
plays	an	important	part	in	the	activity	of	the	OXA-48	enzyme.		
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Conclusion	and	future	work		
The	OXA-23	and	OXA-24	enzymes	proved	to	be	more	difficult	than	expected	to	both	clone	
and	express.	For	OXA-24	the	cloning	difficulties	were	worked	out	by	separating	the	correct	
gene	construct	from	a	shorter,	incorrect	gene	product	on	an	agarose	gel.	But	in	the	end,	we	
were	not	able	to	successfully	express	the	OXA-24	enzyme.	If	time	had	allowed	it,	further	
investigations	might	have	solved	the	problems	and	made	expression	of	the	protein	possible,	
but	as	of	now	the	reason	behind	the	problematic	expression	is	unknown.		
	
The	cloning	of	the	OXA-23	enzyme	resulted	in	a	duplicated	sequence	around	the	His-tag,	
which	might	have	been	the	reason	for	the	weak	expression.	But	the	blaOXA-23	gene	also	
contains	several	rare	codons,	so	it	might	be	necessary	to	optimize	the	gene	sequence	or	the	
host	in	order	to	achieve	over-expression	of	the	protein.		
	
The	OXA-48	enzyme	was	successfully	mutated,	expressed,	purified	and	crystallized.	The	
enzyme	kinetics	studies	showed	that	while	the	R206A	mutant	had	very	similar	activity	to	the	
wild	type	OXA-48,	the	S118G	and	the	R250A	mutants	had	a	significantly	lower	activity	
toward	ampicillin,	imipenem	and	nitrocefin,	which	again	shows	the	importance	of	these	
residues	for	the	overall	OXA-48	enzyme	activity.	The	S118G	mutant	crystal	was	soaked	in	
avibactam	before	data	collection,	and	the	solved	model	did	not	show	avibactam.	But	this	
result	could	be	invalid,	as	avibactam	sample	used	may	not	have	been	valid.	In	addition	to	
doing	this	specific	experiment	once	again	with	a	valid	avibactam	sample,	more	experiments	
can	be	done	here	to	test	the	effect	of	the	mutations	on	the	avibactam	binding	and	
inhibition.		
	
The	OXA-48	mutants	described	in	this	project	will	be	used	in	collaboration	between	Bjarte	
Aarmo	Lund,	Hanna-Kirsti	S.	Leiros,	Geir	Isaksen	and	colleagues	at	the	Brandsdalen	group,	
with	the	aim	of	understanding	the	reaction	mechanism	of	the	OXA-48	using	in	silico	
methods.	In	addition,	potential	inhibitors	are	being	designed	in	collaboration	between	Bjarte	
Aarmo	Lund,	Hanna-Kirsti	S.	Leiros	and	Annette	Bayer’s	group,	guided	by	the	results	of	this	
project.		 	
	
	 84	
References	
	
1.	 World	Economic	Forum,	The	Global	Risks	Report	2016,	11th	edition.	2016.	
2.	 Walker	D.,	F.T.,	Annual	Report	of	the	Chief	Medical	Officer:	Volume	Two,	2011:	
Infections	and	the	Rise	of	Antimicrobial	Resistance	2011,	Department	of	Health.	
3.	 D/'Costa,	V.M.,	et	al.,	Antibiotic	resistance	is	ancient.	Nature,	2011.	477(7365):	p.	
457-461.	
4.	 Kolář,	M.,	K.	Urbánek,	and	T.	Látal,	Antibiotic	selective	pressure	and	development	of	
bacterial	resistance.	International	Journal	of	Antimicrobial	Agents.	17(5):	p.	357-363.	
5.	 Goossens,	H.,	et	al.,	Outpatient	antibiotic	use	in	Europe	and	association	with	
resistance:	a	cross-national	database	study.	(1474-547X	(Electronic)).	
6.	 Barlow,	M.,	What	antimicrobial	resistance	has	taught	us	about	horizontal	gene	
transfer.	(1064-3745	(Print)).	
7.	 Wilke,	M.S.,	A.L.	Lovering,	and	N.C.	Strynadka,	β-lactam	antibiotic	resistance:	a	
current	structural	perspective.	Curr	Opin	Microbiol,	2005.	8(5):	p.	525-33.	
8.	 Konaklieva,	M.I.,	Molecular	Targets	of	β-Lactam-Based	Antimicrobials:	Beyond	the	
Usual	Suspects.	Antibiotics	(Basel),	2014.	3(2):	p.	128-42.	
9.	 American	Chemical	Society	International	Historic	Chemical	Landmarks.	Discovery	and	
Development	of	Penicillin.		[cited	2016	may];	Available	from:	
http://www.acs.org/content/acs/en/education/whatischemistry/landmarks/fleming
penicillin.html		
10.	 Georg,	G.I.,	The	Organic	Chemistry	of	β-Lactams	Journal	of	Chemical	Education,	1993.	
70(9):	p.	A251.	
11.	 Blair,	J.M.A.,	et	al.,	Molecular	mechanisms	of	antibiotic	resistance.	Nat	Rev	Micro,	
2015.	13(1):	p.	42-51.	
12.	 Essack,	S.Y.,	The	development	of	β-lactam	antibiotics	in	response	to	the	evolution	of	
beta-lactamases.	Pharm	Res,	2001.	18(10):	p.	1391-9.	
13.	 Rowe-Magnus,	D.A.	and	D.	Mazel,	The	role	of	integrons	in	antibiotic	resistance	gene	
capture.	Int	J	Med	Microbiol,	2002.	292(2):	p.	115-25.	
14.	 Ambler,	R.P.,	The	structure	of	β-lactamases.	Philos	Trans	R	Soc	Lond	B	Biol	Sci,	1980.	
289(1036):	p.	321-31.	
15.	 Bush,	K.	and	G.A.	Jacoby,	Updated	functional	classification	of	β-lactamases.	
Antimicrob	Agents	Chemother,	2010.	54(3):	p.	969-76.	
16.	 Ghuysen,	J.M.,	Serine	β-lactamases	and	penicillin-binding	proteins.	Annu	Rev	
Microbiol,	1991.	45:	p.	37-67.	
17.	 David	L.	Nelson,	M.M.C.,	Lehninger	Principles	of	Biochemistry.	2008:	W.	H.	Freeman	
and	Company.	1158.	
18.	 Poole,	K.,	Resistance	to	β-lactam	antibiotics.	Cell	Mol	Life	Sci,	2004.	61(17):	p.	2200-
23.	
19.	 Evans,	B.A.	and	S.G.	Amyes,	OXA	β-lactamases.	Clin	Microbiol	Rev,	2014.	27(2):	p.	
241-63.	
20.	 Poirel,	L.,	A.	Potron,	and	P.	Nordmann,	OXA-48-like	carbapenemases:	the	phantom	
menace.	J	Antimicrob	Chemother,	2012.	67(7):	p.	1597-606.	
21.	 Align	Sequences	Protein	BLAST	NCBI	National	Center	for	Biotechnology	Information:	
ncbi.nlm.nih.gov.	
	
	 85	
22.	 Schneider,	K.D.,	et	al.,	Structures	of	the	class	D	carbapenemase	OXA-24	from	
Acinetobacter	baumannii	in	complex	with	doripenem.	J	Mol	Biol,	2011.	406(4):	p.	583-
94.	
23.	 Kaitany,	K.C.,	et	al.,	Structures	of	the	class	D	Carbapenemases	OXA-23	and	OXA-146:	
mechanistic	basis	of	activity	against	carbapenems,	extended-spectrum	
cephalosporins,	and	aztreonam.	Antimicrob	Agents	Chemother,	2013.	57(10):	p.	
4848-55.	
24.	 Docquier,	J.D.,	et	al.,	Crystal	structure	of	the	OXA-48	β-lactamase	reveals	mechanistic	
diversity	among	class	D	carbapenemases.	Chem	Biol,	2009.	16(5):	p.	540-7.	
25.	 Walther-Rasmussen,	J.	and	N.	Hoiby,	OXA-type	carbapenemases.	J	Antimicrob	
Chemother,	2006.	57(3):	p.	373-83.	
26.	 Poirel,	L.,	et	al.,	Acinetobacter	radioresistens	as	a	Silent	Source	of	Carbapenem	
Resistance	for	Acinetobacter	spp.	Antimicrobial	Agents	and	Chemotherapy,	2008.	
52(4):	p.	1252-1256.	
27.	 Smith,	C.A.,	et	al.,	Structural	basis	for	carbapenemase	activity	of	the	OXA-23	β-
lactamase	from	Acinetobacter	baumannii.	Chem	Biol,	2013.	20(9):	p.	1107-15.	
28.	 Bou,	G.,	A.	Oliver,	and	J.	Martínez-Beltrán,	OXA-24,	a	Novel	Class	D	β-Lactamase	with	
Carbapenemase	Activity	in	an	Acinetobacter	baumannii	Clinical	Strain.	Antimicrobial	
Agents	and	Chemotherapy,	2000.	44(6):	p.	1556-1561.	
29.	 Poirel,	L.,	et	al.,	Emergence	of	oxacillinase-mediated	resistance	to	imipenem	in	
Klebsiella	pneumoniae.	Antimicrob	Agents	Chemother,	2004.	48(1):	p.	15-22.	
30.	 Drawz,	S.M.	and	R.A.	Bonomo,	Three	Decades	of	β-Lactamase	Inhibitors.	Clinical	
Microbiology	Reviews,	2010.	23(1):	p.	160-201.	
31.	 Drawz,	S.M.,	K.M.	Papp-Wallace,	and	R.A.	Bonomo,	New	β-Lactamase	Inhibitors:	a	
Therapeutic	Renaissance	in	an	MDR	World.	Antimicrobial	Agents	and	Chemotherapy,	
2014.	58(4):	p.	1835-1846.	
32.	 Ehmann,	D.E.,	et	al.,	Avibactam	is	a	covalent,	reversible,	non-β-lactam	beta-
lactamase	inhibitor.	Proc	Natl	Acad	Sci	U	S	A,	2012.	109(29):	p.	11663-8.	
33.	 Ehmann,	D.E.,	et	al.,	Kinetics	of	Avibactam	Inhibition	against	Class	A,	C,	and	D	β-
Lactamases.	The	Journal	of	Biological	Chemistry,	2013.	288(39):	p.	27960-27971.	
34.	 Lahiri,	S.D.,	et	al.,	Molecular	basis	of	selective	inhibition	and	slow	reversibility	of	
avibactam	against	class	D	carbapenemases:	a	structure-guided	study	of	OXA-24	and	
OXA-48.	ACS	Chem	Biol,	2015.	10(2):	p.	591-600.	
35.	 Danel,	F.,	et	al.,	Effect	of	divalent	metal	cations	on	the	dimerization	of	OXA-10	and	-
14	class	D	β-lactamases	from	Pseudomonas	aeruginosa.	Biochemistry,	2001.	40(31):	
p.	9412-20.	
36.	 Carl	Branden,	J.T.,	Introduction	to	Protein	Structure	2nd	ed.	1999:	Garland	Science,	
Taylor	and	Francis	Group,	LLC		
37.	 Nelson,	D.L.	and	M.M.	Cox,	Lenhinger	Principles	of	Biochemistry	5th	ed.	2008,	New	
York,	US.	:	W.	H.	Freeman	and	Company		
38.	 Lund,	B.A.,	H.K.	Leiros,	and	G.E.	Bjerga,	A	high-throughput,	restriction-free	cloning	
and	screening	strategy	based	on	ccdB-gene	replacement.	Microb	Cell	Fact,	2014.	
13(1):	p.	38.	
39.	 Bond,	S.R.	and	C.C.	Naus,	RF-Cloning.org:	an	online	tool	for	the	design	of	restriction-
free	cloning	projects.	Nucleic	Acids	Res,	2012.	40(Web	Server	issue):	p.	W209-13.	
40.	 Waugh,	D.S.,	TEV	Protease	FAQ,	N.C.I.	Macromolecular	Crystallography	Laboratory,	
US.	,	Editor.	2010.	
	
	 86	
41.	 Petersen,	T.N.,	et	al.,	SignalP	4.0:	discriminating	signal	peptides	from	transmembrane	
regions.	Nat	Methods,	2011.	8(10):	p.	785-6.	
42.	 Macherey-Nagel,	User	manual	NucleoSpin®	Gel	and	PCR	Clean-up.	2014.	
43.	 Promega	Corporation,	Wizard®	Plus	SV	Minipreps	DNA	Purification	System.	2009.	
44.	 Applied	Biosystems,	BigDye®	Terminator	v3.1	Cycle	Sequencing	Kit	Protocol.	2010.	
45.	 Zhang,	Z.,	et	al.,	A	greedy	algorithm	for	aligning	DNA	sequences.	J	Comput	Biol,	2000.	
7(1-2):	p.	203-14.	
46.	 Wilkins,	M.R.,	et	al.,	Protein	identification	and	analysis	tools	in	the	ExPASy	server.	
Methods	Mol	Biol,	1999.	112:	p.	531-52.	
47.	 Agilent	Technologies.	QuikChange	Primer	Design	2015		[cited	2015;	Available	from:	
http://www.genomics.agilent.com/primerDesignProgram.jsp?&_requestid=153764.	
48.	 GE	Healthcare	Bio-Sciences,	Affinity	Chromatography	Principles	and	Methods.	2007.	
p.	47-51.	
49.	 Bornhorst,	J.A.	and	J.J.	Falke,	Purification	of	proteins	using	polyhistidine	affinity	tags.	
Methods	Enzymol,	2000.	326:	p.	245-54.	
50.	 Stevens,	R.C.,	High-throughput	protein	crystallization.	Curr	Opin	Struct	Biol,	2000.	
10(5):	p.	558-63.	
51.	 Rhodes,	G.,	Crystallography	Made	Crystal	Clear	3rd	ed.	Complementary	Science	
Series	2006,	Oxford,	UK	Elsevier	Inc.	.	
52.	 McCoy,	A.J.,	et	al.,	Phaser	crystallographic	software.	J	Appl	Crystallogr,	2007.	40(Pt	
4):	p.	658-674.	
53.	 Bjarte	Aarmo	Lund,	et	al.,	Screening	and	design	of	inhibitor	scaffolds	for	the	antibiotic	
resistance	enzyme	OXA-48	through	surface	plasmon	resonance	screening.	Under	
Revision	2016.	
54.	 Adams,	P.D.,	et	al.,	PHENIX:	a	comprehensive	Python-based	system	for	
macromolecular	structure	solution.	Acta	Crystallogr	D	Biol	Crystallogr,	2010.	66(Pt	2):	
p.	213-21.	
55.	 Emsley,	P.	and	K.	Cowtan,	Coot:	model-building	tools	for	molecular	graphics.	Acta	
Crystallogr	D	Biol	Crystallogr,	2004.	60(Pt	12	Pt	1):	p.	2126-32.	
56.	 GraphPad	Software	Inc.,	GraphPad	Prism	7.	2016		
57.	 Bio-Sciences,	G.H.,	Size	Exclusion	Chromatography	Principles	and	Methods.	2014.	
58.	 National	Center	for	Biotechnology	Information.	Align	Sequences	Nucleotide	BLAST.	
2016		[cited	2016;	Available	from:	
http://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE=MegaBlast&PROGRAM=blastn&BLAST_
PROGRAMS=megaBlast&PAGE_TYPE=BlastSearch&BLAST_SPEC=blast2seq&DATABAS
E=n/a&QUERY=&SUBJECTS=.	
59.	 LLC,	G.B.	SnapGene	Viewer	2.6.2.	2015;	Available	from:	
http://www.snapgene.com/products/snapgene_viewer/.	
60.	 ExPASy	Bioinformatics	Resource	Portal.	Translate	tool.	2016;	Available	from:	
http://web.expasy.org/translate/.	
61.	 Dreyer,	B.,	Interpretation	of	sequencing	electropherogram	data	The	DNA	sequencing	
core	facility	HelseNord,	Editor.	2004.	
62.	 Online	Dictionary	of	CRYSTALLOGRAPHY.	Free	R	factor	2016		[cited	2016	may];	
Available	from:	http://reference.iucr.org/dictionary/Free_R_factor.	
63.	 Mura,	C.,	Rare	Codon	Calculator	(RaCC).	NIH	MBI	Laboratory	Servers	UCLA			
64.	 Kane,	J.F.,	Effects	of	rare	codon	clusters	on	high-level	expression	of	heterologous	
proteins	in	Escherichia	coli.	Curr	Opin	Biotechnol,	1995.	6(5):	p.	494-500.	
	
	 87	
65.	 Rosano,	G.L.	and	E.A.	Ceccarelli,	Recombinant	protein	expression	in	Escherichia	coli:	
advances	and	challenges.	Front	Microbiol,	2014.	5:	p.	172.	
66.	 Santillana,	E.,	et	al.,	Crystal	structure	of	the	carbapenemase	OXA-24	reveals	insights	
into	the	mechanism	of	carbapenem	hydrolysis.	Proc	Natl	Acad	Sci	U	S	A,	2007.	
104(13):	p.	5354-9.	
67.	 GE	Healthcare	Life	Sciences,	Strategies	for	Protein	Purification.	2010.	
68.	 Schmit,	J.D.	and	K.	Dill,	Growth	rates	of	protein	crystals.	J	Am	Chem	Soc,	2012.	134(9):	
p.	3934-7.	
69.	 Papp-Wallace,	K.M.,	et	al.,	Variants	of	β-lactamase	KPC-2	that	are	resistant	to	
inhibition	by	avibactam.	Antimicrob	Agents	Chemother,	2015.	59(7):	p.	3710-7.	
70.	 Winkler,	M.L.,	et	al.,	Avibactam	and	inhibitor-resistant	SHV	β-lactamases.	Antimicrob	
Agents	Chemother,	2015.	59(7):	p.	3700-9.	
	
